Supplementary materials: Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Appendix A: Systematic Literature Review

• Table S1: Summary of inclusion and exclusion criteria for the systematic literature review.

Appendix B: PRISMA Flow Diagram

• Figure S1: PRISMA flow diagram.

Appendix C: Feasibility Assessment

• Table S2: Overview of feasibility assessment by outcome.

Appendix D: STC Analysis: Additional Details and Sensitivity Analyses

• Table S3: Factors adjusted in each base case STC analysis.
• Figure S2: SLEDAI reduction STC sensitivity analysis: Inclusion of MUSE
• Figure S3: SRI(4) response STC sensitivity analysis: Inclusion of MUSE
• Figure S4: BILAG flares STC sensitivity analysis: Inclusion of MUSE
• Figure S5: OCS reduction STC sensitivity analysis: Inclusion of MUSE

Aim: Assess the comparative efficacy of anifrolumab 300 mg versus belimumab 10 mg/kg in adults with moderate-to-severe systemic lupus erythematosus (SLE) receiving standard therapy. Patients and methods: Population-adjusted simulated treatment comparisons (primary analyses) and matching-adjusted indirect comparisons (supporting analyses) were conducted using individual patient data from TULIP-1/TULIP-2 and summary-level data from BLISS-52/BLISS-76. Results: Compared with belimumab-treated patients, anifrolumab-treated patients were more than twice as likely to achieve a reduction of four or more points in SLE Disease Activity Index 2000 score (simulated treatment comparison odds ratio: 2.47; 95% CI: 1.16–5.25) and SLE Responder Index-4 response (odds ratio: 2.61; 95% CI: 1.22–5.58) at 52 weeks. Conclusion: Patients with moderate-to-severe SLE are more likely to achieve an improvement in disease activity with anifrolumab than with belimumab.